Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Isomorphic Labs 是一家专注于人工智能药物发现的平台，成立于2021年，源自谷歌的 DeepMind。近日，该公司 首次 获得外部融资，共计6亿美元轮融资由 Thrive Capital 领投，参与者包括 GV 和现有投资者 ...